<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Feb 09)
Joaqu√≠n C√°ceres C, Cardenas-Garcia S, et int., and Perez DR. [‚ÄúEfficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.‚Äù](/search/?article=Caceres21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.27.428428](https://doi.org/10.1101/2021.01.27.428428). \[[PubMed33532776](https://www.ncbi.nlm.nih.gov/pubmed/33532776/)\] \[[PMC7852269](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852269/)\]
### Database Entries (Feb 09)
Li W, Sch√§fer A, et int., and Dimitrov DS. [‚ÄúHigh Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.‚Äù](/search/?article=Li20j) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.007](https://doi.org/10.1016/j.cell.2020.09.007). \[[PubMed32941803](https://www.ncbi.nlm.nih.gov/pubmed/32941803/)\] \[[PMC7473018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473018/)\]
### Database Entries (Feb 09)
Rappazzo CG, Tse LV, et int., and Walker LM. [‚ÄúBroad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.‚Äù](/search/?article=Rappazzo21) _Science_, 2021. [doi.org/10.1126/science.abf4830](https://doi.org/10.1126/science.abf4830). \[[PubMed33495307](https://www.ncbi.nlm.nih.gov/pubmed/33495307/)\]
### Database Entries (Feb 06)
Joyner MJ, Carter RE, et int., and Casadevall A. [‚ÄúConvalescent Plasma Antibody Levels and the Risk of Death from Covid-19.‚Äù](/search/?article=Joyner21) _New England Journal of Medicine_, 2021. [doi.org/10.1056/nejmoa2031893](https://doi.org/10.1056/nejmoa2031893). \[[PubMed33523609](https://www.ncbi.nlm.nih.gov/pubmed/33523609/)\] \[[PMC7821984](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821984/)\]
### [Clinical Trials (Feb 04)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-02-04)
### Database Entries (Jan 31)
White KM, Rosales R, et int., and Garc√≠a-Sastre A. [‚ÄúPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.‚Äù](/search/?article=White21) _Science (New York, N.Y.)_, None. [doi.org/10.1126/science.abf4058](https://doi.org/10.1126/science.abf4058). \[[PubMed33495306](https://www.ncbi.nlm.nih.gov/pubmed/33495306/)\]
### [Clinical Trials (Jan 28)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-28)
### Database Entries (Jan 25)
Gottlieb RL, Nirula A, et int., and Skovronsky DM. [‚ÄúEffect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19.‚Äù](/search/?article=Gottlieb21) _JAMA_, 2021. [doi.org/10.1001/jama.2021.0202](https://doi.org/10.1001/jama.2021.0202). \[[PubMed33475701](https://www.ncbi.nlm.nih.gov/pubmed/33475701/)\]
### [Clinical Trials (Jan 21)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-21)
### Database Entries (Jan 19)
Davies SP, Mycroft-West CJ, et int., and Richardson A. [‚ÄúThe hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models.‚Äù](/search/?article=Davies21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.10.426114](https://doi.org/10.1101/2021.01.10.426114).
### Database Entries (Jan 19)
Kim C, Ryu D, et int., and Lee S. [‚ÄúA therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.‚Äù](/search/?article=Kim21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20602-5](https://doi.org/10.1038/s41467-020-20602-5). \[[PubMed33436577](https://www.ncbi.nlm.nih.gov/pubmed/33436577/)\]
### Database Entries (Jan 19)
McCallum M, Marco AD, et int., and Veesler D. [‚ÄúN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.‚Äù](/search/?article=McCallum21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.14.426475](https://doi.org/10.1101/2021.01.14.426475).
### Database Entries (Jan 19)
Tada T, Fan C, et int., and Landau NR. [‚ÄúAn ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.‚Äù](/search/?article=Tada20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.108528](https://doi.org/10.1016/j.celrep.2020.108528). \[[PubMed33326798](https://www.ncbi.nlm.nih.gov/pubmed/33326798/)\] \[[PMC7705358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705358/)\]
### Database Entries (Jan 15)
Biering SB, Van Dis E, et int., and Stanley SA. [‚ÄúScreening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2.‚Äù](/search/?article=Biering20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.30.424862](https://doi.org/10.1101/2020.12.30.424862).
### [Clinical Trials (Jan 14)](/page/updates/#clinical.trials)
[13 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-14)
### Database Entries (Jan 12)
Kirti R, Roy R, et int., and Sarfaraz A. [‚ÄúIvermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial.‚Äù](/search/?article=Kirti21) _medRxiv_, 2021. [doi.org/10.1101/2021.01.05.21249310](https://doi.org/10.1101/2021.01.05.21249310).
